WaveMan
WaveMan · Company
ELV · Elevance Health, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELV Elevance Health (ELV) Insider Trading, Ownership & Congress Trades

Insurance · Hospital & medical service plans · CIK 0001156039
Quote by TradingView
C-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
867
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $450.6K priced

What the filings say about ELV

Insiders, 180 days
-$4.1M net sold
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-08-13
Planned sales (Form 144), 90 days
$4.7M
1 notice

Elevance Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Elevance Health, Inc. insiders sold a net $4.1M of stock across 59 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kaye Mark
EVP & CFO
SELL
2026-10-23 SECtraded 2026-10-22
400
$173.6K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 24, 2025.
  • The trade is 1.3% of the 30,103 shares held after it.
  • No other insider sold within 30 days.
  • 867 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Kaye Mark sold about $173.6K of ELV on Oct 22, 2026; 867 funds added in the latest 13F quarter.
Kaye Mark
EVP & CFO
SELL
2026-10-23 SECtraded 2026-10-22
321
$139.7K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 24, 2025.
  • The trade is 1.1% of the 29,782 shares held after it.
  • No other insider sold within 30 days.
  • 867 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Kaye Mark sold about $139.7K of ELV on Oct 22, 2026; 867 funds added in the latest 13F quarter.
Kaye Mark
EVP & CFO
SELL
2026-10-23 SECtraded 2026-10-22
1,660
$724.1K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 24, 2025.
  • The trade is 5.9% of the 28,122 shares held after it.
  • No other insider sold within 30 days.
  • 867 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Kaye Mark sold about $724.1K of ELV on Oct 22, 2026; 867 funds added in the latest 13F quarter.
Kaye Mark
EVP & CFO
SELL
2026-10-23 SECtraded 2026-10-22
560
$244.8K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 24, 2025.
  • The trade is 2.0% of the 27,562 shares held after it.
  • No other insider sold within 30 days.
  • 867 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Kaye Mark sold about $244.8K of ELV on Oct 22, 2026; 867 funds added in the latest 13F quarter.
Kaye Mark
EVP & CFO
SELL
2026-10-23 SECtraded 2026-10-22
240
$105.2K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 24, 2025.
  • The trade is 0.9% of the 27,322 shares held after it.
  • No other insider sold within 30 days.
  • 867 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Kaye Mark sold about $105.2K of ELV on Oct 22, 2026; 867 funds added in the latest 13F quarter.
59 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 54 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.1M over 180 days
-$4.7M over 90 days
below 59% of Insurance
Congress
no House purchase disclosed in the last 12 months
Funds
867 funds bought in last quarter
more than 94% of Insurance
Revenue
+12.5% year over year
more than 60% of Insurance
Margin
2.8% net margin
below 75% of Insurance
Buybacks
$1.7B repurchased, FY to 2026-09-30
more than 94% of Insurance
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
below 64% of Insurance
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 23EVP & CFO Kaye Mark sold $4.7M (Oct 22)
Oct 22Officer MARK B KAYE filed to sell $4.7M by Oct 22 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ELV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+29.4%12M
-18%-2%+15%+31%2025-102025-122026-022026-042026-062026-082026-10 2026-10-22 · Kaye Mark sold $1.0M2026-03-06 · Kendrick Charles Morgan JR sold $910.6K2026-03-05 · COLLIS STEVEN H bought $869.5K2026-10-22 · Kaye Mark sold $757.6K2026-07-17 · BOUDREAUX GAIL bought $753.1K2026-10-22 · Kaye Mark sold $724.1K2026-05-19 · Penczek Ronald W sold $617.2K2026-10-22 · Kaye Mark sold $509.5K2026-10-22 · Kaye Mark sold $368.9K2026-07-17 · PERU RAMIRO G bought $366.1K2026-07-17 · BOUDREAUX GAIL bought $249.2K2026-10-22 · Kaye Mark sold $244.8K2026-10-22 · Kaye Mark sold $212.5K2026-10-22 · Kaye Mark sold $195.3K2026-10-22 · Kaye Mark sold $173.6K2026-06-12 · Penczek Ronald W sold $148.8K2026-10-22 · Kaye Mark sold $139.7K2026-10-22 · Kaye Mark sold $122.1K2026-10-22 · Kaye Mark sold $105.2K2026-10-22 · Kaye Mark sold $71.2K2026-06-11 · Dixon Robert L JR sold $60.7K2026-03-12 · SCHULMAN AMY W sold $7.5K2026-10-22 · MARK B KAYE filed to sell $4.7M2026-07-07 · CLARK R KERRY filed to sell $629.9K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELV: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
18,991,090 sh
$7.3B
VANGUARD CAPITAL MANAGEMENT LLC
14,058,204 sh
$5.4B
STATE STREET CORP
10,426,610 sh
$4.0B
WELLINGTON MANAGEMENT GROUP LLP
9,213,513 sh
$3.6B
First Eagle Investment Management, LLC
8,376,392 sh
$3.2B

Congress trades in ELV

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Lisa McClain
Sold 2025-08-13 · disclosed 30 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-08-05 · disclosed 38 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-07-10 · disclosed 34 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-06-24 · disclosed 50 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-05-30 · disclosed 7 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ELV planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MARK B KAYE
Filed 2026-10-22
$4.7M
CLARK R KERRY
Filed 2026-07-07
$629.9K

ELV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Health Care Services Portfolio
$85.4M position · as of 2026-05-31
10.6%
iShares U.S. Healthcare Providers ETF
$84.0M position · as of 2026-06-30
7.1%
Artisan Select Equity Fund
$5.1M position · as of 2026-06-30
5.2%
Artisan Global Value Fund
$139.2M position · as of 2026-06-30
4.3%
Sequoia Fund Inc
$149.7M position · as of 2026-06-30
4.1%
Dana Concentrated Dividend ETF
$1.8M position · as of 2026-05-31
4.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included. Not annual revenue (USASpending.gov).
Department Of Health And Human Services
J6 A/B MAC SERVICES · 2020-08-01
$569.0M
Department Of Health And Human Services
NEXT GENERATION DESKTOP IGF::OT::IGF · 2017-02-01
$505.3M
Department Of Health And Human Services
PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK) · 2022-01-01
$483.6M
Department Of Health And Human Services
SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE · 2025-01-27
$21.8M
Department Of Health And Human Services
THE CONTRACTOR SHALL PROVIDE SUPPLIES AND/OR SERVICES TO PROVIDE A SINGLE FRONT-END SOLUTION FOR THE · 2022-08-11
$20.0M
Department Of Health And Human Services
THE CONTRACTOR SHALL ISSUE PAYMENTS AND PROVIDE RELATED PAYMENT SERVICES TO WTC ELIGIBLE PROVIDERS I · 2022-05-01
$6.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Elevance Health, Inc. Political Action Committee (Elevance Health Pac)
Cycle 2026 · $2,528K spent
$2.2M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Gail Boudreaux
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$22.6M
$18.8M
$7.2M
+17%
+48%
2024
$20.5M
-$4.0M
$6.3M
+21%
+29%
2023
$21.9M
$16.2M
$8.9M
+52%
+26%
2022
$20.9M
$35.3M
$6.7M
+63%
+24%
2021
$19.3M
$50.4M
$6.4M
+46%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.1M sold by insiders over 180 days, 867 funds added last quarter, $4.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
GSHDDGICAPLMRALHCCRVLHGTYKNSLAFLTRVMKLOSCRGL

ELV financials

Revenue growth
+12.5%
XBRL, annual
Net margin
2.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$201.8B
four quarters, 2025-10-01 to 2026-09-30
Net margin, TTM
+2.5%
net income over revenue, 2025-10-01 to 2026-09-30
Free cash flow, TTM
$6.5B
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Debt to equity
0.69x
long-term 2026-09-30 plus current 2026-09-30; equity 2026-09-30
Cash flow to debt
0.25x
TTM operating cash flow over long-term 2026-09-30 plus current 2026-09-30
Return on equity
+11.6%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets
+4.1%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on invested capital
+6.8%
operating income after a 18.4% effective tax rate, over long-term 2026-09-30 plus current 2026-09-30 plus average of 2025-09-30 and 2026-09-30 minus cash
Return on capital employed
+6.7%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
P/E, trailing
18.71x
close 2026-10-23 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
Enterprise value
$115.5B
market value at close 2026-10-23 on 2026-10-15 shares, plus long-term 2026-09-30 plus current 2026-09-30, minus cash 2026-09-30
FCF yield
+6.9%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing EPS growth -4%, PEG needs growth
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$199.1B$177.0B$171.3B$156.6B
Operating income$7.2B$7.9B$8.5B$8.3B
Net income$5.7B$6.0B$6.0B$5.9B
EPS (diluted)25.2125.6825.2224.28
Operating cash flow$4.3B$5.8B$8.1B$8.4B
Cash$9.5B$8.3B$6.5B$7.4B
Long-term debt$30.8B$29.2B$23.2B$22.3B
Buybacks$2.6B$2.9B$2.7B$2.3B
Dividends paid$1.5B$1.5B$1.4B$1.2B
SEC XBRL, fiscal years, as known on 2026-10-27

ELV Stock Sonar score 6/7 axes

Find similar shapesCompare

ELV ranks highest on institutional and government (96th percentile) and risk and compliance (65th), and lowest on financial health (24th), among Insurance peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
48
Inputs
  • Return on equity+11.6% · 38 pct, sector of 116
  • Return on assets+4.1% · 61 pct, sector of 122
  • Return on invested capital+6.8% · 25 pct, universe of 1,069
  • Return on capital employed+6.7% · 66 pct, universe of 3,236
Financial health
24
Inputs
  • Debt to equity0.69x · 18 pct, sector of 104
  • Cash flow to debt0.25x · 30 pct, sector of 97
Growth
60
Inputs
  • Revenue growth, YoY+12.5% · 60 pct, sector of 134
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
63
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.1M · 39 pct, sector of 100
  • Insider buyers, 180d2 · 87 pct, sector of 101
Institutional and government
96
Inputs
  • Funds adding, latest quarter867 · 94 pct, sector of 108
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$11.2M · 97 pct, sector of 35
Risk and compliance
65
Inputs
  • Short interest, % of float+2.2% · 73 pct, sector of 138
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.2% · 58 pct, sector of 110
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ELV filings, in plain words

Are Elevance Health insiders buying or selling ELV?

In the 180 days to 2026-10-27, Elevance Health insiders were net sellers, a net $4.1M: $1.4M of purchases and $5.5M of sales reported on Form 4, by 2 buyers and 3 sellers.

Have members of Congress traded ELV?

Yes, but not in the year to 2026-10-27; the latest on record is a sale by Lisa McClain dated 2025-08-13.

Are there planned insider sales of ELV?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $4.7M of stock; the latest, by MARK B KAYE, was filed 2026-10-22.

Read the full summary

In the 180 days to 2026-10-27, Elevance Health insiders were net sellers of ELV, a net $4.1M across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. None of the 16 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in ELV, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-08-13. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $4.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies